<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23123001</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1879-114X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical therapeutics</Title>
          <ISOAbbreviation>Clin Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.</ArticleTitle>
        <Pagination>
          <StartPage>2185</StartPage>
          <EndPage>2194</EndPage>
          <MedlinePgn>2185-94</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinthera.2012.10.003</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0149-2918(12)00568-1</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Medication used to treat multiple sclerosis (MS) can be categorized as disease-modifying therapies, symptomatic therapies, or treatment of acute exacerbations. Dalfampridine is the first symptomatic therapy approved by the Food and Drug Administration to improve walking in patients with MS.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This article reviews the pharmacology, pharmacodynamic properties, and pharmacokinetic properties of dalfampridine, as well as its clinical efficacy, safety profile, pharmacoeconomic considerations, and place in therapy.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Three PubMed searches were conducted for original articles published in English between 1966 and August 2012 with human study participants. Articles concerning the pharmacology, pharmacokinetic properties, pharmacodynamic properties, efficacy, and safety profile of dalfampridine were evaluated.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Dalfampridine theoretically works to improve conduction and enhance walking by inhibiting potassium channels in the axonal membrane and by prolonging action potentials in demyelinated neurons. The efficacy of dalfampridine has been reported in 2 Phase III clinical trials in patients with MS. When comparing dalfampridine 10 mg twice daily with placebo, these studies found a statistically significant improvement in walking (42.9% vs 9.3% and 35% vs 8%; P &lt; 0.001). However, clinical trials and postmarketing surveillance have shown an increased risk of seizures with dalfampridine use that appears to be dose related [corrected].</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Dalfampridine has a unique mechanism of action, leading to its approval as the first symptomatic therapy for MS to improve walking speed. The increased risk of seizures can be a safety concern and will require health care providers to be diligent in monitoring patients and to ensure adequate patient education [corrected]. The addition of dalfampridine as symptomatic therapy for MS may lead to additional novel products in the future.</AbstractText>
          <CopyrightInformation>Copyright Â© 2012 Elsevier HS Journals, Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Egeberg</LastName>
            <ForeName>Michael D</ForeName>
            <Initials>MD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Pharmacy, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oh</LastName>
            <ForeName>Caleb Y</ForeName>
            <Initials>CY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bainbridge</LastName>
            <ForeName>Jacquelyn L</ForeName>
            <Initials>JL</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Clin Ther</MedlineTA>
        <NlmUniqueID>7706726</NlmUniqueID>
        <ISSNLinking>0149-2918</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D026902">Potassium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BH3B64OKL9</RegistryNumber>
          <NameOfSubstance UI="D015761">4-Aminopyridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Clin Ther. 2013 Jun;35(6):900</RefSource>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015761" MajorTopicYN="N">4-Aminopyridine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016527" MajorTopicYN="N">Drug Costs</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005684" MajorTopicYN="N">Gait</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020233" MajorTopicYN="N">Gait Disorders, Neurologic</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026902" MajorTopicYN="N">Potassium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016138" MajorTopicYN="Y">Walking</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23123001</ArticleId>
        <ArticleId IdType="doi">10.1016/j.clinthera.2012.10.003</ArticleId>
        <ArticleId IdType="pii">S0149-2918(12)00568-1</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
